Clinical trial
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV)…
NCT04886596 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT04886596 |
|---|---|
| Title | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above |
| Official title | A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Infections |
| Intervention type | Biological |
| Interventions | Placebo, RSVPreF3 OA vaccine |
| Enrollment | 26,675 |
| Start date | May 25, 2021 |
| Primary completion | Apr 11, 2022 |
| Completion | May 31, 2024 |
| First posted | May 14, 2021 |
| Last update posted | Jul 31, 2025 |
| Countries | Australia, Belgium, Canada, Estonia, Finland, Germany, Italy, Japan, Mexico, New Zealand, Poland, Russia and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: